- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07827599
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants (Pearlstone)
A Phase III, Randomized, Double-blinded, Placebo-controlled Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in participants who are household contacts (HHCs) of participants with influenza (index participants).
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry
Studer Kontakt Backup
- Navn: Roche Pharma (Schweiz) AG Reference Study ID Number: YV46459, https://forpatients.roche.com/
- Telefonnummer: 888-662-6728 (U.S. Only)
- E-post: global-roche-genentech-trials@gene.com
Studiesteder
-
-
-
Changde, Kina, DUMMY_VALUE
- Rekruttering
- The First People's Hospital of Changde
-
Huizhou, Kina, 516001
- Rekruttering
- Huizhou Central People's Hospital
-
Ningbo, Kina, 315000
- Rekruttering
- Ningbo No.2 Hospital
-
Sanmenxia, Kina, DUMMY_VALUE
- Rekruttering
- Sanmenxia Central Hospital
-
Shanghai, Kina, 200040
- Rekruttering
- Huashan Hospital Affiliated to Fudan University
-
Xiamen, Kina, 361001
- Rekruttering
- Xiamen Maternal and Child Health Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510280
- Rekruttering
- Zhujiang Hospital, Southern Medical University
-
-
Sichuan
-
Mianyang, Sichuan, Kina, 621000
- Rekruttering
- Mianyang Central Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Index Participants (Participants With Influenza Virus Infection):
- First participant in a household with influenza virus infection in the current influenza season
- Fewer than 6 HHCs
- Agreement by all household members to participate in the study and comply with the study protocol for the duration of the study
- Diagnosed as having influenza with positive rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) result
- Onset of symptoms within 48 hours or less at time of signing Informed Consent Form (ICF)/Assent Form
- PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care or local laboratory test
HHCs of Index Participants:
- Lived with the index participant for 48 hours or more prior to informed consent/assent
- Meet all the following criteria and are judged not to have influenza virus infection by the investigator: body temperature (tympanic) <37.5 degrees Celsius (°C); no influenza-like symptoms (cough, sore throat, headache, nasal discharge/nasal congestion, feverishness or chills, muscle or joint pain, or fatigue) at screening; negative RIDT or PCR result for influenza
- For participants 12 years of age or older, ability to evaluate influenza symptoms by using a participant influenza symptoms diary; For participants under 12 years of age, capability of parents/caregivers to evaluate influenza symptoms by using a participant influenza symptoms diary
- PCR (-) or antigen test (-) for SARS-CoV-2 using point-of-care or local laboratory test
Exclusion Criteria:
HHCs of Index Participants:
- Diagnosed with influenza during the current influenza season
- Unable to live with the index patient from screening until Day 10
- Live with a household member who has any influenza-like symptom(s) other than the index participant on the day of screening
- Live with household members other than the index participant who was diagnosed with or strongly suspected to have influenza during the current influenza season
- Have any underlying diseases requiring systemic (oral or injection), or nasal treatment of antipyretics/analgesics, corticosteroids, or immunosuppressive agents
- Immunocompromised
- Use of any medications with anti-influenza effect within 30 days prior to screening
- Known allergy and/or history of significant intolerance against baloxavir marboxil
- Exposure to an investigational drug within 30 days or 5 half-lives of the drug prior to screening, whichever is longer
Note: Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Baloxavir Marboxil
HHCs will receive baloxavir marboxil according to their body weight as outlined in the protocol. |
Baloxavir marboxil will be administered to the HHCs as per the schedule specified in the protocol.
Andre navn:
|
|
Placebo komparator: Placebo
HHCs will receive baloxavir marboxil matching placebo according to their body weight as outlined in the protocol. |
Baloxavir marboxil matching placebo will be administered to the HHCs as per the schedule specified in the protocol. |
|
Ingen inngripen: No Intervention
Index participants will not receive any study treatment but will continue to receive SOC treatment for influenza, as per the local guidelines. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of Participants who are Infected With Influenza Virus (Reverse Transcription - Polymerase Chain Reaction [RT-PCR] Positive), and Present With Fever and at Least one Respiratory Symptom
Tidsramme: From Day 1 up to Day 10
|
From Day 1 up to Day 10
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive), and Present With Fever or at Least one Influenza Symptom (Respiratory or Systemic)
Tidsramme: From Day 1 up to Day 10
|
From Day 1 up to Day 10
|
|
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive) Regardless of Body Temperature or Influenza Symptoms
Tidsramme: From Day 1 up to Day 10
|
From Day 1 up to Day 10
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to Day 21
|
Up to Day 21
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- YV46459
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .